Ragosa Mark 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Jan 9, 2026
Insider Transaction Report
Form 4
Ragosa Mark
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Class A Ordinary Share
2026-01-08$41.89/sh−12,000$502,680→ 19,086 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.44 and $42.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.